A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

Prior treatment

• Acute coronary syndrome event or stroke within 24 weeks prior to Day 1. Acute pancreatitis within 12 weeks prior to Day 1.
• Positive serology for HIV, hepatitis B or hepatitis C (antibody, surface antigen orNAT). Serology consistent with prior immunization will be eligible for the trial.

Other illness

• Participants with familial chylomicronemia syndrome (FCS). Some exceptions may apply.
• Abnormal or compromised function of kidney, heart, blood or liver.
• Any prior malignancy within the past 5 years, or current malignancy (exceptions for resected or removed basal cell carcinoma, squamous cell carcinoma in situ and carcinoma in situ of the cervix or breast).

Lab values

• Evidence of liver disease, defined as but not limited to:
  • LFTS \>2 × upper limit of normal (ULN), or total bilirubin \>2 × ULN, or INR \>1.5 × ULN, or liver stiffness measured by liver elastography

Other

• Current use or use within 365 days from Day 1 of any hepatocyte-targeted small interfering RNA (except inclisiran).
• Women of childbearing potential.
  • Note: Other protocol defined Inclusion/Exclusion criteria may apply.
  • Note: The inclusion and exclusion criteria listed represent the global protocol. Additional or modified eligibility criteria may apply in certain countries in accordance with local regulatory and ethics committee requirements and the approved country-specific protocol.

• Age of ≥18 and ≤75 years at the time of signing the informed consent.
• Able to provide written informed consent.
• Participants diagnosed with persistent dyslipidemias defined by TG ≥150 mg/dL - and LDL-C ≥70 mg/dL in participants with ASCVD, or LDL-C ≥70 or 100mg/dL in participants with or without ASCVD respectively, or TG ≥500 mg/dL.
• Refractory to the maximal intensity or MTD of standard of care lines of lipid-lowering therapies available through routine clinical care, for at least 12 weeks prior to screening
• Female participants must be postmenopausal or surgically sterile.
• All male participants and their female partners must agree to the use of an acceptable method of effective contraception for the duration of the study.